6-K · 2026-11-03
Vicore Pharma Holding AB has revealed its nomination committee for the 2027 Annual General Meeting, involving key shareholders and governance preparations.
| Name | Vicore Pharma Holding AB |
|---|---|
| CIK | 0002124403 |
| Tickers | VCRE |
| Exchanges | Nasdaq |
| Entity type | other |
| Category | — |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | V7 Sweden |
| Phone | 46(0)317880560 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 0 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Vicore Pharma Holding AB has revealed its nomination committee for the 2027 Annual General Meeting, involving key shareholders and governance preparations.
Vicore Pharma's ASPIRE trial for buloxibutid in IPF continues after a positive review, aiming for mid-2027 topline results.
13 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-05 | 6-K | FORM 6-K | 0001437749-26-035333 | 001-43312 | 261528504 | 34 | 7036884 | |||
| 2026-11-03 | 6-K | FORM 6-K | 0001437749-26-034704 | 001-43312 | 261519079 | 34 | 26012 | |||
| 2026-10-22 | 6-K | FORM 6-K | 0001437749-26-033290 | 001-43312 | 261479474 | 34 | 32972 | |||
| 2026-10-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-115489 | 005-95960 | 261456902 | 34 | 8521 | |||
| 2026-09-30 | 6-K | FORM 6-K | 0001437749-26-031613 | 001-43312 | 261427852 | 34 | 24219 | |||
| 2026-08-21 | S-8 | FORM S-8 | 0001104659-26-099739 | 333-298501 | 261305674 | 33 | 653415 | 1 | 1 | |
| 2026-08-21 | 6-K | FORM 6-K | 0001104659-26-099719 | 001-43312 | 261305265 | 34 | 5219861 | |||
| 2026-07-06 | 6-K | FORM 6-K | 0001104659-26-080617 | 001-43312 | 261154451 | 34 | 21251 | |||
| 2026-06-30 | SEC STAFF ACTION | filename1.pdf | 9999999997-26-001144 | 135856 | ||||||
| 2026-06-30 | CERT | 2124403_20F_Cert_VCRE.pdf | 0001354457-26-000627 | 001-43312 | 261139926 | 34 | 182860 | |||
| 2026-06-09 | 20FR12B/A | 20FR12B/A | 0001104659-26-071924 | 001-43312 | 261077176 | 34 | 4278327 | |||
| 2026-05-22 | 20FR12B | 20FR12B | 0001104659-26-065450 | 001-43312 | 261010830 | 34 | 5660016 | |||
| 2026-04-17 | DRS | filename1.htm | 0001104659-26-044746 | 377-09269 | 26870544 | 33 | 4629121 |
One latest value per concept from companyfacts (4 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ffd | NetFeeAmt | NetFeeAmt | USD | 5,094.98 | 2026-08-21 | S-8 | 2026-08-21 | 0001104659-26-099739 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 5,094.98 | 2026-08-21 | S-8 | 2026-08-21 | 0001104659-26-099739 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 36.89M | 2026-08-21 | S-8 | 2026-08-21 | 0001104659-26-099739 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-21 | S-8 | 2026-08-21 | 0001104659-26-099739 |